Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN

Michelandrea De Cesare, Lucia Sfondrini, Manuela Campiglio, Michele Sommariva, Francesca Bianchi, Paola Perego, Nico Van Rooijen, Rosanna Supino, Cristiano Rumio, Franco Zunino, Graziella Pratesi, Elda Tagliabue, Andrea Balsari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P

Original languageEnglish
Pages (from-to)8-15
Number of pages8
JournalJournal of Immunotherapy
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Ascites
Carcinoma
Survival
Neoplasms
Abdominal Cavity
Oligodeoxyribonucleotides
Peritoneal Cavity
Growth
Intraperitoneal Injections
Nude Mice
Ovarian Neoplasms
Cell Count
Therapeutics

Keywords

  • Antitumor activity
  • Ascites
  • CpG-ODN
  • Orthotopic model
  • Ovarian cancer

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. / De Cesare, Michelandrea; Sfondrini, Lucia; Campiglio, Manuela; Sommariva, Michele; Bianchi, Francesca; Perego, Paola; Van Rooijen, Nico; Supino, Rosanna; Rumio, Cristiano; Zunino, Franco; Pratesi, Graziella; Tagliabue, Elda; Balsari, Andrea.

In: Journal of Immunotherapy, Vol. 33, No. 1, 01.2010, p. 8-15.

Research output: Contribution to journalArticle

De Cesare, M, Sfondrini, L, Campiglio, M, Sommariva, M, Bianchi, F, Perego, P, Van Rooijen, N, Supino, R, Rumio, C, Zunino, F, Pratesi, G, Tagliabue, E & Balsari, A 2010, 'Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN', Journal of Immunotherapy, vol. 33, no. 1, pp. 8-15. https://doi.org/10.1097/CJI.0b013e3181affaa7
De Cesare, Michelandrea ; Sfondrini, Lucia ; Campiglio, Manuela ; Sommariva, Michele ; Bianchi, Francesca ; Perego, Paola ; Van Rooijen, Nico ; Supino, Rosanna ; Rumio, Cristiano ; Zunino, Franco ; Pratesi, Graziella ; Tagliabue, Elda ; Balsari, Andrea. / Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. In: Journal of Immunotherapy. 2010 ; Vol. 33, No. 1. pp. 8-15.
@article{800e1562763d4aabaf7517990ea7b302,
title = "Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN",
abstract = "Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P",
keywords = "Antitumor activity, Ascites, CpG-ODN, Orthotopic model, Ovarian cancer",
author = "{De Cesare}, Michelandrea and Lucia Sfondrini and Manuela Campiglio and Michele Sommariva and Francesca Bianchi and Paola Perego and {Van Rooijen}, Nico and Rosanna Supino and Cristiano Rumio and Franco Zunino and Graziella Pratesi and Elda Tagliabue and Andrea Balsari",
year = "2010",
month = "1",
doi = "10.1097/CJI.0b013e3181affaa7",
language = "English",
volume = "33",
pages = "8--15",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN

AU - De Cesare, Michelandrea

AU - Sfondrini, Lucia

AU - Campiglio, Manuela

AU - Sommariva, Michele

AU - Bianchi, Francesca

AU - Perego, Paola

AU - Van Rooijen, Nico

AU - Supino, Rosanna

AU - Rumio, Cristiano

AU - Zunino, Franco

AU - Pratesi, Graziella

AU - Tagliabue, Elda

AU - Balsari, Andrea

PY - 2010/1

Y1 - 2010/1

N2 - Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P

AB - Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P

KW - Antitumor activity

KW - Ascites

KW - CpG-ODN

KW - Orthotopic model

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=74349104485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74349104485&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3181affaa7

DO - 10.1097/CJI.0b013e3181affaa7

M3 - Article

C2 - 19952960

AN - SCOPUS:74349104485

VL - 33

SP - 8

EP - 15

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 1

ER -